Peptide Therapy: What It Is, How It Works, Types & Costs (2026)

Overview

Peptide therapy refers to the clinical use of peptides — short chains of amino acids that function as signaling molecules — to treat or manage specific health conditions. These compounds bind to receptors on cell surfaces and trigger targeted biological responses, offering a degree of precision that distinguishes them from many conventional pharmaceuticals. In 2026, peptide therapy spans a broad spectrum: from FDA-approved medications prescribed by physicians at major medical centers to investigational compounds offered through specialized clinics and telehealth platforms. The regulatory landscape is complex and rapidly evolving. FDA-approved peptide drugs like semaglutide and tirzepatide have undergone rigorous clinical trials involving tens of thousands of participants and represent the gold standard of evidence. At the other end of the spectrum, research peptides like BPC-157 and Ipamorelin are offered by compounding pharmacies and peptide clinics under varying levels of medical oversight, often with extensive preclinical data but limited human clinical trial evidence. Peptide therapy is offered by a growing network of providers including endocrinologists, anti-aging medicine practitioners, functional medicine clinics, sports medicine physicians, and telehealth platforms specializing in metabolic health. The market has expanded dramatically, driven in large part by the clinical success of GLP-1 agonists for weight management and the broader public interest in peptides for recovery, performance, and longevity. This guide provides an evidence-based overview of what peptide therapy involves, who offers it, what the different types are, what costs to expect, and what the current safety and regulatory considerations are. All information is educational — peptide therapy decisions should always be made in consultation with a qualified healthcare provider.

What Is Peptide Therapy?

Peptide therapy is a medical or clinical approach that uses synthetic or bioidentical peptides to modulate specific biological pathways in the body. Peptides are molecules composed of 2 to 50 amino acids linked by peptide bonds — smaller than proteins but larger than individual amino acids — and they serve as highly specific signaling molecules that can influence hormone release, immune function, tissue repair, metabolism, and neurological processes. The concept behind peptide therapy is straightforward: by introducing peptides that mimic or enhance the body's own signaling molecules, clinicians aim to restore, optimize, or modulate physiological functions that may be impaired due to aging, disease, injury, or other factors. For example, growth hormone secretagogues like CJC-1295 and Ipamorelin stimulate the pituitary gland to release growth hormone in a pattern that mimics the body's natural pulsatile secretion — rather than administering exogenous growth hormone directly. Similarly, GLP-1 receptor agonists like semaglutide replicate the effects of the incretin hormone GLP-1, which the body naturally produces in the gut to regulate appetite and blood sugar. The term "peptide therapy" is used broadly and can refer to FDA-approved prescription medications, compounded peptide preparations prescribed by physicians, or research peptides administered under clinical supervision. This range of applications and regulatory statuses is a source of both opportunity and confusion for patients. Understanding the distinction between rigorously validated FDA-approved peptide drugs and less-studied compounds available through clinics or compounding pharmacies is essential for making informed decisions about peptide therapy.

How Peptide Therapy Works: Mechanisms of Action

Peptide therapy works by leveraging the body's existing receptor-signaling infrastructure. When a therapeutic peptide is administered — whether by subcutaneous injection, oral delivery, intranasal spray, or topical application — it enters circulation and binds to specific receptors on target cells, triggering a cascade of intracellular events that produce the desired biological effect. The specificity of this receptor-ligand interaction is what gives peptide therapy its precision. Different classes of therapeutic peptides work through distinct mechanisms. GLP-1 receptor agonists such as semaglutide and tirzepatide bind to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract. In the pancreas, this stimulates insulin secretion and suppresses glucagon release. In the hypothalamus, it activates satiety centers that reduce appetite. In the stomach, it slows gastric emptying, prolonging the feeling of fullness after meals. The combined effect produces significant reductions in caloric intake and improved glycemic control. Growth hormone secretagogues operate through a different pathway. GHRH analogs like CJC-1295 and Sermorelin bind to GHRH receptors on somatotroph cells in the anterior pituitary gland, directly stimulating the synthesis and release of growth hormone. Ghrelin mimetics like Ipamorelin bind to the growth hormone secretagogue receptor (GHS-R), amplifying growth hormone pulses. The resulting elevation in growth hormone and its downstream mediator IGF-1 influences lean body mass, fat metabolism, bone density, sleep quality, and tissue repair. Tissue repair peptides like BPC-157 appear to work through multiple mechanisms including upregulation of growth factor receptors (particularly the GH receptor and EGF receptor), promotion of angiogenesis (new blood vessel formation), modulation of the nitric oxide system, and activation of FAK-paxillin pathways involved in cell migration and wound healing. GHK-Cu, a copper-binding tripeptide, activates tissue remodeling genes and stimulates collagen and glycosaminoglycan synthesis. PT-141, the FDA-approved sexual health peptide, activates melanocortin-4 receptors in the hypothalamus, stimulating neural pathways involved in sexual arousal through a mechanism entirely independent of vascular blood flow — distinguishing it from phosphodiesterase inhibitors like sildenafil. The bioavailability and duration of action of each peptide depend on its molecular structure, route of administration, and any modifications engineered to extend its half-life. For instance, semaglutide has been albumin-engineered to achieve a seven-day half-life suitable for once-weekly dosing, while unmodified peptides like BPC-157 have much shorter half-lives and may require more frequent administration.

• GLP-1 agonists (semaglutide, tirzepatide): Bind GLP-1 receptors to reduce appetite, slow gastric emptying, and improve insulin signaling
• Growth hormone secretagogues (CJC-1295, Ipamorelin, Sermorelin): Stimulate pituitary GH release through GHRH or GHS-R receptor activation
• Tissue repair peptides (BPC-157, TB-500, GHK-Cu): Promote angiogenesis, growth factor receptor upregulation, and extracellular matrix remodeling
• Melanocortin agonists (PT-141): Activate MC4R receptors in the hypothalamus to modulate sexual arousal pathways
• Immune peptides (Thymosin Alpha-1): Enhance T-cell maturation and dendritic cell activation to strengthen adaptive immunity

Types of Peptide Therapy

Peptide therapy encompasses a broad range of compounds organized by their primary therapeutic application. The major categories reflect the diversity of biological systems that peptide signaling can influence, from metabolic regulation and body composition to tissue healing, cognitive function, and immune support. Understanding these categories helps patients and practitioners identify which peptide therapies are relevant to specific health goals and — critically — which ones have strong clinical evidence versus preliminary preclinical data. GLP-1 receptor agonists represent the most clinically validated category of peptide therapy. Semaglutide (marketed as Wegovy for weight management and Ozempic for type 2 diabetes) and tirzepatide (Zepbound and Mounjaro) have demonstrated transformative results in large randomized controlled trials. Tirzepatide, a dual GIP/GLP-1 receptor agonist, produced up to 22.5% mean body weight reduction in the SURMOUNT-1 trial. The investigational triple-agonist retatrutide achieved 24.2% weight loss in phase 2 trials. These represent the strongest evidence base of any peptide therapy category. Growth hormone secretagogue therapy uses peptides like CJC-1295, Ipamorelin, Sermorelin, and GHRP-2 to stimulate the body's natural growth hormone production. This approach is used in clinical settings for age-related growth hormone decline, body composition optimization, recovery support, and sleep quality improvement. Tesamorelin is the only FDA-approved GHRH analog, indicated for HIV-associated lipodystrophy. Other secretagogues are available through compounding pharmacies under physician prescription. Tissue repair and healing peptide therapy centers on compounds like BPC-157, TB-500, and GHK-Cu. These are among the most commonly prescribed peptides at sports medicine and regenerative health clinics, used for tendon, ligament, and joint injuries as well as post-surgical recovery and gastrointestinal healing. BPC-157 has over 100 published preclinical studies but lacks completed human clinical trials. GHK-Cu is available both as an injectable peptide and in topical skincare formulations. Cognitive and neuroprotective peptide therapy includes compounds like Selank and Semax, which are approved as medications in Russia for anxiety and cognitive enhancement, respectively. These peptides modulate neurotransmitter systems and brain-derived neurotrophic factor (BDNF) expression. Immune modulation therapy uses peptides such as Thymosin Alpha-1, which is approved in over 30 countries for hepatitis and immune deficiency, to enhance adaptive immune function. Sexual health peptide therapy is anchored by PT-141 (bremelanotide), FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

• GLP-1 agonists for weight management: semaglutide, tirzepatide, liraglutide, retatrutide (investigational)
• Growth hormone secretagogues for body composition and recovery: CJC-1295, Ipamorelin, Sermorelin, tesamorelin
• Tissue repair peptides for healing and injury recovery: BPC-157, TB-500, GHK-Cu, Thymosin Beta-4
• Cognitive and neuroprotective peptides: Selank, Semax, Dihexa, cerebrolysin
• Immune modulation peptides: Thymosin Alpha-1, LL-37, KPV
• Sexual health peptides: PT-141 (bremelanotide), kisspeptin
• Longevity and mitochondrial peptides: Epithalon, MOTS-c, SS-31
• Sleep and recovery peptides: DSIP, Selank

Who Offers Peptide Therapy: Clinics, Telehealth, and Physicians

The provider landscape for peptide therapy has expanded significantly as demand has grown, and the type of provider matters enormously in terms of quality of care, regulatory compliance, and safety monitoring. Understanding where peptide therapy is offered — and the differences between provider types — helps patients make informed choices. Endocrinologists and internal medicine physicians are the traditional providers for FDA-approved peptide medications. Semaglutide, tirzepatide, and other prescription peptide drugs are available through standard medical channels — a physician writes a prescription, and the patient fills it at a licensed pharmacy. This pathway offers the highest level of regulatory oversight and product quality assurance. Telehealth platforms specializing in metabolic health and weight management have become a major access point for peptide therapy, particularly for GLP-1 agonists. These platforms typically connect patients with licensed physicians who conduct virtual consultations, order lab work, and prescribe FDA-approved medications or compounded peptide preparations that are shipped directly to the patient. The convenience of telehealth has made peptide therapy accessible to patients who may not have local specialists. Anti-aging and functional medicine clinics represent the fastest-growing segment of peptide therapy providers. These clinics typically offer a broader range of peptide therapies including growth hormone secretagogues (CJC-1295 and Ipamorelin protocols), tissue repair peptides (BPC-157, TB-500), and immune peptides (Thymosin Alpha-1). Protocols are usually designed by physicians with training in regenerative or functional medicine, and peptides are sourced from compounding pharmacies that prepare custom formulations under physician prescription. Sports medicine and regenerative medicine clinics often incorporate peptide therapy as part of comprehensive injury recovery and performance optimization programs. These settings may combine peptide therapy with other regenerative approaches such as platelet-rich plasma (PRP) therapy, stem cell treatments, and physical rehabilitation. Compounding pharmacies play a critical role in the peptide therapy ecosystem. These pharmacies prepare custom peptide formulations — often as lyophilized powders that patients reconstitute with bacteriostatic water before injection — under a physician's prescription. The quality and regulatory oversight of compounding pharmacies varies, and the FDA has raised concerns about consistency and purity of some compounded products. Patients should verify that their compounding pharmacy is accredited and follows current Good Manufacturing Practice standards. Our reconstitution calculator can help patients understand proper peptide preparation, though all reconstitution and dosing should follow physician instructions.

• Endocrinologists and primary care physicians: FDA-approved peptide prescriptions through standard medical channels
• Telehealth platforms: Virtual consultations with licensed physicians for GLP-1 agonists and compounded peptides
• Anti-aging and functional medicine clinics: Broader peptide protocols including secretagogues and repair peptides
• Sports medicine and regenerative clinics: Peptide therapy integrated with injury recovery programs
• Compounding pharmacies: Custom peptide formulations prepared under physician prescription

What to Expect: Consultation, Labs, Dosing, and Monitoring

A responsible peptide therapy program follows a structured process that includes initial evaluation, baseline laboratory testing, individualized protocol design, and ongoing monitoring. Understanding this process helps patients set realistic expectations and identify providers who follow appropriate medical standards. The initial consultation typically involves a comprehensive medical history review, discussion of health goals, current medications and supplements, and identification of any contraindications. For GLP-1 agonist therapy, providers will evaluate BMI, metabolic markers, personal and family history of thyroid disease (particularly medullary thyroid carcinoma), pancreatitis history, and current medications that may interact with peptide therapy. For growth hormone secretagogue protocols, providers assess baseline hormone levels, body composition, and any history of pituitary disorders or malignancy. Baseline laboratory testing is a standard component of quality peptide therapy programs. Typical panels include comprehensive metabolic panel (CMP), complete blood count (CBC), hemoglobin A1c, fasting insulin, lipid panel, thyroid function tests (TSH, free T3, free T4), and hormone panels (testosterone, estradiol, IGF-1, DHEA-S). For growth hormone secretagogue therapy specifically, baseline IGF-1 levels are essential for monitoring response and safety. Some providers also order inflammatory markers (CRP, ESR), liver function tests, and kidney function panels. Protocol design varies by peptide type and provider. GLP-1 agonists follow standardized dose escalation schedules — semaglutide starts at 0.25 mg weekly and escalates over 16-20 weeks to the maintenance dose of 2.4 mg. Tirzepatide starts at 2.5 mg and escalates to a maximum of 15 mg. Growth hormone secretagogue protocols often involve daily or five-days-per-week subcutaneous injections, frequently administered before bedtime to align with the body's natural nocturnal growth hormone release. BPC-157 and other tissue repair peptides are typically dosed in cycles of 4-12 weeks. Our dosage calculator provides general reference information, though all dosing decisions must be made by a prescribing physician. Ongoing monitoring is essential for safety and efficacy. Follow-up appointments typically occur at 4-8 week intervals initially, then every 3-6 months once a stable protocol is established. Repeat laboratory testing tracks treatment response and screens for adverse effects — IGF-1 levels for secretagogue therapy, metabolic panels for GLP-1 agonists, and general health markers across all protocols. Responsible providers adjust protocols based on laboratory results, symptom response, and side effect profiles rather than using fixed protocols for all patients.

• Initial consultation: Medical history, health goals, contraindication screening, and medication review
• Baseline labs: CMP, CBC, HbA1c, lipid panel, thyroid panel, hormone panel (IGF-1, testosterone), inflammatory markers
• Protocol design: Individualized dosing schedules with appropriate escalation periods based on compound and patient response
• Administration training: Instruction on subcutaneous injection technique, peptide reconstitution, and proper storage
• Follow-up monitoring: Labs at 4-8 week intervals initially, then every 3-6 months; protocol adjustments based on response
• Typical treatment duration: GLP-1 agonists are often long-term; secretagogues may be cycled; repair peptides are used in defined courses

Peptide Therapy Costs: What to Expect in 2026

The cost of peptide therapy varies enormously depending on the specific compound, whether it is a brand-name FDA-approved medication or a compounded preparation, insurance coverage, and the provider setting. Understanding the cost landscape is essential for patients evaluating peptide therapy options. Brand-name GLP-1 agonists represent the highest-cost tier of peptide therapy. Without insurance, semaglutide (Wegovy) carries a list price of approximately $1,350 per month, while tirzepatide (Zepbound) is priced at approximately $1,000-$1,060 per month. Insurance coverage for these medications has expanded significantly but remains inconsistent — many plans cover them for type 2 diabetes but not for weight management alone, and prior authorization requirements are common. Manufacturer savings programs and patient assistance programs can reduce out-of-pocket costs for eligible patients. Compounded GLP-1 agonists have emerged as a lower-cost alternative during periods of branded product shortage. Compounded semaglutide and tirzepatide preparations from accredited compounding pharmacies typically cost $200-$500 per month, though the FDA has issued guidance regarding the conditions under which compounded versions of these drugs may be prepared. Patients should verify that their compounding pharmacy is accredited by the Pharmacy Compounding Accreditation Board (PCAB) or holds equivalent certification. Our cost calculator can help estimate monthly expenses based on peptide type and dosing protocol. Growth hormone secretagogue therapy through clinics typically costs $150-$400 per month depending on the specific peptides used and whether single or combination protocols are prescribed. CJC-1295 and Ipamorelin combination protocols — among the most commonly prescribed secretagogue regimens — generally fall in the $200-$350 per month range from compounding pharmacies. Sermorelin-based protocols may be slightly less expensive. These costs usually include the peptide itself but not initial consultation fees, laboratory testing, or follow-up visits. Tissue repair peptide therapy costs vary by compound and treatment duration. BPC-157 protocols typically range from $150-$300 per treatment cycle (usually 4-8 weeks), while GHK-Cu preparations may cost $100-$250 per month depending on formulation (injectable versus topical). TB-500 is priced similarly to BPC-157 in most clinic settings. Additional costs to factor into peptide therapy budgets include initial consultation fees ($150-$500 depending on provider type), laboratory testing ($200-$600 for comprehensive baseline panels, though insurance may cover standard labs), follow-up visits ($75-$250 per visit), and supplies such as bacteriostatic water, syringes, and alcohol swabs ($20-$40 per month). Some clinics offer bundled pricing that includes consultation, labs, peptides, and follow-up monitoring in a single monthly fee, typically ranging from $300-$800 per month for non-GLP-1 protocols.

• Brand-name GLP-1 agonists: $1,000-$1,350/month without insurance (semaglutide, tirzepatide)
• Compounded GLP-1 agonists: $200-$500/month from accredited compounding pharmacies
• Growth hormone secretagogues: $150-$400/month for CJC-1295, Ipamorelin, or Sermorelin protocols
• Tissue repair peptides: $150-$300 per treatment cycle for BPC-157; $100-$250/month for GHK-Cu
• Initial consultation: $150-$500 depending on provider type and comprehensiveness
• Baseline laboratory panels: $200-$600 (may be partially covered by insurance)
• Follow-up visits: $75-$250 per visit, typically every 4-8 weeks initially
• Bundled clinic programs: $300-$800/month for comprehensive non-GLP-1 peptide protocols

Safety and Regulatory Considerations

Safety and regulatory considerations are paramount in peptide therapy, and the landscape varies dramatically between FDA-approved medications and compounds available through clinics and compounding pharmacies. Patients and practitioners must understand these distinctions to make informed decisions. FDA-approved peptide therapies have undergone the most rigorous safety evaluation. Semaglutide and tirzepatide were studied in clinical trial programs involving over 10,000 participants each, with comprehensive adverse event monitoring and post-market surveillance. Their side effect profiles are well-characterized: the most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea, constipation), typically occurring during dose escalation and diminishing over time. Both carry boxed warnings regarding the risk of thyroid C-cell tumors based on animal data, and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis has been reported as a rare adverse event. PT-141 (Vyleesi) has a known safety profile from its clinical development program, with nausea and injection-site reactions as the most common side effects. Compounded and research peptides carry a different risk profile. Compounds like BPC-157, CJC-1295, Ipamorelin, and TB-500 have varying levels of preclinical safety data — BPC-157, for example, has over 100 published animal studies with a favorable safety profile, but the absence of completed human clinical trials means that the full human safety profile remains formally unknown. Beyond the inherent pharmacological risks, compounded peptides introduce additional concerns related to product quality: purity, sterility, accurate dosing, and proper storage all depend on the compounding pharmacy's quality control processes. The FDA has increased scrutiny of compounding pharmacies producing peptide products and has taken enforcement actions against those making unsubstantiated therapeutic claims or operating outside regulatory boundaries. The regulatory environment for peptide therapy is evolving rapidly. In 2023-2024, the FDA began more actively reviewing the status of peptides on its bulk drug substances list for compounding, and several peptides have faced regulatory challenges. Patients should be aware that the availability of specific compounded peptides may change as regulatory decisions are made. Working with a licensed healthcare provider who stays current on regulatory developments and sources peptides from accredited compounding pharmacies is essential for minimizing risk. Any individual considering peptide therapy should consult a qualified healthcare provider who can evaluate their specific medical history, screen for contraindications, order appropriate baseline and monitoring laboratory work, and adjust protocols based on individual response. Self-administration of peptides without medical supervision carries meaningful risks including drug interactions, unrecognized contraindications, contaminated or mislabeled products, and the inability to properly monitor for adverse effects.

• FDA-approved peptides (semaglutide, tirzepatide, PT-141): Well-characterized safety profiles from large clinical trials with post-market surveillance
• Compounded peptides (BPC-157, CJC-1295, Ipamorelin): Varying preclinical safety data; human safety profiles not formally established through clinical trials
• Product quality risks: Compounded peptide purity, sterility, and dosing accuracy depend on pharmacy quality control standards
• Regulatory evolution: FDA actively reviewing peptide compounding; availability of specific compounds may change
• Contraindication screening: Essential before starting any peptide therapy — includes thyroid disease history, pancreatitis, malignancy, and medication interactions
• Ongoing monitoring: Regular laboratory testing and follow-up visits are necessary to track both efficacy and adverse effects
• Medical supervision: All peptide therapy should be conducted under the guidance of a licensed healthcare provider

References

1. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (2021) — PubMed
2. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (2022) — PubMed
3. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023) — PubMed
4. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review) (2020) — PubMed
5. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts (2011) — PubMed
6. Therapeutic peptides: historical perspectives, current development trends, and future directions (2022) — PubMed